insulin

Generic Name: insulin

Clinical Trials

Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus

Phase 3

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: ORMD-0801

First Posted Date: 2021-03-26

Last Posted Date: 2021-03-26

Lead Sponsor: King Hamad University Hospital, Bahrain

Target Recruit Count: 608

Registration Number: NCT04817215

Effect of Ultrasonographic Guided Insulin Injection With Dexamethasone and Local Anesthetic Mixture in Diabetic Patients With Mild to Moderate Carpal Tunnel .

Not Applicable

Conditions: Pain Relief

Interventions: Drug: insulin

First Posted Date: 2021-03-04

Last Posted Date: 2021-03-04

Lead Sponsor: Minia University

Target Recruit Count: 250

Registration Number: NCT04781777

A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus

Phase 3

Terminated

Conditions: T2DM (Type 2 Diabetes Mellitus)

Interventions: Drug: ORMD-0801
Other: Placebo

First Posted Date: 2021-02-15

Last Posted Date: 2023-02-09

Lead Sponsor: Oramed, Ltd.

Target Recruit Count: 346

Registration Number: NCT04754334

Locations: 🇺🇸
Research Institute of South Florida, Inc. (PHARMASEEK), Coral Gables, Florida, United States

Post-operative Complications and Graft Survival With Conventional Versus Continuous Glucose Monitoring in Patients With Diabetes Mellitus Undergoing Renal Transplantation

Early Phase 1

Completed

Conditions: Diabetes Mellitus

Interventions: Diagnostic Test: Finger Stick Glucose Measurement
Device: Continuous Glucose Monitor Application
Device: Continuous Glucose Monitor Placebo Applied
Drug: Insulin

First Posted Date: 2021-02-05

Last Posted Date: 2023-12-26

Lead Sponsor: Northwell Health

Target Recruit Count: 40

Registration Number: NCT04742023

Locations: 🇺🇸
North Shore University Hospital, Manhasset, New York, United States

A Trial to Investigate Hyperglycemic and Hypoglycemic Excursions in Subjects With Type 1 Diabetes

Early Phase 1

Completed

Conditions: Type 1 Diabetes Mellitus With Hypoglycemia

Interventions: Drug: Insulin
Drug: Glucagon

First Posted Date: 2021-01-15

Last Posted Date: 2021-01-15

Lead Sponsor: Abvance Therapeutics

Target Recruit Count: 15

Registration Number: NCT04712266

Locations: 🇺🇸
Atlanta Diabetes Associates, Atlanta, Georgia, United States

The Effect of Intranasal Insulin on Motor and Non-motor Symptoms in Parkinson's Disease Patients

Phase 2

Completed

Conditions: Parkinson Disease

Interventions: Drug: Insulin
Drug: Normal saline

First Posted Date: 2020-12-29

Last Posted Date: 2024-04-23

Lead Sponsor: dr.dargahi

Target Recruit Count: 28

Registration Number: NCT04687878

Locations: 🇮🇷
Shahid Beheshti University of Medical Sciences, Shohada-e-Tajrish Hospital, Tehran, Iran, Islamic Republic of

Post Operative Delirium Study

Phase 1

Withdrawn

Conditions: Delirium

Interventions: Drug: Insulin
Drug: Saline

First Posted Date: 2020-11-19

Last Posted Date: 2024-08-21

Lead Sponsor: University of Kansas Medical Center

Registration Number: NCT04635774

Locations: 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States

Intravenous Insulin vs Subcutaneous Insulin Infusion in Intrapartum Management of Type 1 Diabetes Mellitus

Phase 4

Completed

Conditions: Type 1 Diabetes
Pregnancy, High Risk

Interventions: Drug: Insulin

First Posted Date: 2020-10-22

Last Posted Date: 2024-07-08

Lead Sponsor: Gianna Wilkie

Target Recruit Count: 70

Registration Number: NCT04599075

Locations: 🇺🇸
University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States

A Study to Evaluate the Effect of ORMD-0801 in Patients With Type 2 Diabetes Mellitus

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: ORMD-0801
Other: Placebo

First Posted Date: 2020-09-25

Last Posted Date: 2024-05-07

Lead Sponsor: Oramed, Ltd.

Target Recruit Count: 49

Registration Number: NCT04564846

Locations: 🇺🇸
Orange County Research Center (OCRC) 14351 Myford Rd., Suite B, Tustin, CA 92780, Tustin, California, United States

Intensive Insulin Therapy as Therapeutic Strategy for Non-diabetic Hyperglycemia After Surgery in ICU

Not Applicable

Completed

Conditions: Hyperglycemia
Postoperative Complications
Insulin Resistance

Interventions: Drug: Insulin

First Posted Date: 2020-09-18

Last Posted Date: 2021-03-09

Lead Sponsor: Tanta University

Target Recruit Count: 86

Registration Number: NCT04554615

Locations: 🇸🇦
Security Forces Hospital, Riyadh, Saudi Arabia

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy